Capricor's shares went up 15.22% to $10.22, even though it lost 73 cents per share last quarter.

Nov 11, 2026, 10:33 AM ETResultsRead the original at Benzinga

Neutral

Capricor missed the loss estimate, but its cash, added two-year results, and launch-ready site support the drug effort. FDA approval remains pending, so these opposing facts do not clearly change the outlook.

CAPR · Capricor Therapeutics Inc.

AI read · Neutral

The AI's read

The $199 million cash balance gives Capricor resources as it prepares for a possible launch. New two-year results and a ready San Diego site help, but the FDA has not approved deramiocel. The larger-than-expected loss pulls the other way, so the story does not clearly shift the outlook.

Get alerts for CAPR

Follow Capricor Therapeutics Inc. (CAPR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CAPR

Free on the App Store and Google Play, or on the web.